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Abstract
Background/Aim.  Selective intraarterial radionuclide
therapy (SIRT) with Yttrium-90 (Y-90) microspheres is
also known as radioembolization and delivers high doses
of radiation to hepatic tumors with minimum healthy liver
exposure. The aim of this study was to present our pre-
liminary experience in the role of liver directed radiother-
apy with Y-90 microspheres for the treatment of unre-
sectable hepatic metastases from neuroendocrine tumors
(NET). Methods. The results of SIRT in 10 patients (5
males, 5 females; mean age 48.7 years; age range 24–73
years) with metastatic liver disease from NETs during the
period from April 2008 through August 2010 were re-
viewed. All patients had meticulous pre- and post-imaging
studies as a part of their work-up procedure, as well as se-
rologic tests of liver function to determine the extent of
liver function damage. The patients who were eligible for
SIRT had pretreatment visceral angiography to define and
occlude non-target arteries. Results. The mean ± SD ad-
ministered SIR-Spheres® activity was 1.49 ± 0.42 GBq
(range 0.72–2.21 GBq) in all the patients. These treat-
ments delivered a dose of 99.73 ± 66.36 Gy (range 49–
420.8 Gy) to the target tumors. The estimated dose to the
lungs and normal liver was 4.45 ± 1.95 Gy (range 2.4–8.5
Gy) and 26.73 ± 14.19 Gy (range 5–58.9 Gy), respectively.
Overall response rate of 90% and patient tolerance was
satisfactory for most patients. Conclusion. From our lim-
ited experience, we can conclude that SIRT with Y-90 mi-
crospheres is a safe and efficacious treatment option for
patients with liver metastasis of NET without any serious
side effects.
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Apstrakt
Uvod/Cilj. Selektivno intraarterijsko radionuklidno leče-
nje (selective intraarterial radionuclide therapy – SIRT) prime-
nom mikrosfera sa itrijumom-90 (Y-90) poznato je kao ra-
dioembolizacija kojom se hepatički tumori zrače visokom
dozom radijacije uz minimalno izlaganje zdravog dela jet-
re. Cilj ove studije bio je prikazivanje našeg prvog saznanja
o ulozi SIRT, primenom mikrosfera Y-90, kod neoperabil-
nih hepatičkih metastaza sa poreklom od neuroendokrinih
tumora (NET). Metode. Prikazani su rezultati SIRT kod
10 bolesnika (pet muškaraca i pet žena, srednje starosti
48,7 godina, u rasponu od 24 do 73 godine) sa metastat-
skim oboljenjem jetre izazvanim NET u periodu od aprila
2008. do avgusta 2010. Svi bolesnici prošli su kroz detaljno
ispitivanje pre i posle snimanja, što je deo procedure, kao i
kroz serološka ispitivanja funkcije jetre kako bi se utvrdio
stepen njenog funkcijskog oštećenja. Bolesnicima koji su
bili određeni za SIRT urađena je visceralna angiografija pre
početka lečenja da bi se definisale i okludirale neciljne arte-
rije. Rezultati. Prosečna aktivnost datih mikrosfera (SIR-
Spheres®) iznosila je 1,49  ±  0,42 GBq (opseg 0,72–2,21
GBq) kod svih bolesnika. Ovim tretmanom ciljni tumori
ozračeni su dozom od 99,73 ± 66,36 Gy (opseg 49–420,8
Gy). Procenjena doza za pluća i zdravu jetru bila je
4,45  ±  1,95 Gy (opseg 2,4–8,5 Gy) i 26,73  ±  14,19 Gy
(opseg 5–58,9 Gy), respektivno. Ukupni terapijski odgovor
od 90% i podnošljivost tretmana bili su zadovoljavajući
kod većine bolesnika. Zaključak. Prema našem ograniče-
nom iskustvu možemo zaključiti da SIRT primenom mi-
krosfera sa Y-90 predstavlja sigurni i efikasni način lečenja
bolesnika sa metastazama u jetri nastalih zbog NET i to
bez ozbiljnijih neželjenih dejstava.
Ključne reči:
neuroendokrini tumori; jetra; neoplazme, metastaze;
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Introduction
One of the most important prognostic factors that dra-
matically affects survival of a patient with neuroendocrine
tumor (NET) is the presence of liver metastasis. It has been
shown that patients with liver metastasis have a worse sur-
vival rate compared to those without liver involvement in all
types or digestive NETs 
1, 2. Liver metastasis has a negative
impact on survival with a 10–20% 10-year survival com-
pared to 90–100% without liver metastases 
3. Unfortunately,
the majority of patients with NETs (up to 60–75%) already
present with liver metastases. In particular, patients with
non-functioning tumor (without hormonal symptoms) mostly
present with liver disease in up to 50% of the cases 
1. Besides
that, patients with liver metastases present an overall poor
prognosis compared to those without liver metastases for all
NETs regardless of the primary 
3.
Although surgical resection remains the gold standard
in the treatment of liver metastases achieving a survival rate
of 60–80% at 5 years with low mortality (0–5%) and accept-
able morbidity (close up to 30%), only a limited number of
patients can meet the minimum requirements for curative
surgical procedures
 4–6. Another possible therapy option for
carefully selected patients with diffuse unresectable liver
metastases or who suffer from severe hormonal disturbances
refractory to medical therapy is liver transplantation. How-
ever, a long-term cure from the disease by transplantation
will be an exceptional event even in this highly selected sub-
group 
7.
Local ablative techniques such as radiofrequency abla-
tion (RFA)
 8, 9, selective hepatic transcatheter arterial emboli-
zation (TAE)
 10, 11 or chemoembolization (TACE) with he-
patic artery occlusion
 12, 13, can be employed in the treatment
of unresectable liver metastases from NETs regardless of  the
origin of the primary tumor. Nonetheless, these ablative
therapies as well as some others such as laser therapy, etha-
nol injection or cryotherapy are applicable to a small propor-
tion of patients with few tumors
 14–16.
Symptoms related with hormonal hypersecretion are
frequent in functional tumors with liver metastases. Somato-
statin analogues (with or without interferon) are often effec-
tive and helpful in controlling these symptoms 
17. However,
medical therapies with somatostatin analogues and/or inter-
feron have weak antiproliferative effects 
18. Systemic che-
motherapy with streptozotocin achieves modest response
rates of limited duration and is better for pancreatic NETs
compared with metastatic carcinoid tumors 
19. A randomized
study using doxorubicin with fluorouracil or streptozocin
with fluorouracil followed by dacarbazine in the patients at
disease progression of metastatic carcinoids demonstrated re-
sponse rate of 8.2% with significant treatment related toxic-
ity 
20. On the other hand, peptide receptor related radionu-
clide therapy may be used in the treatment of metastatic
NETs, with 90 Y-DOTATOC and 177 Lu-DOTATOC re-
vealing particular promise
 21, 22.
Radioembolization with Yttrium-90 (Y-90) labeled
microspheres has shown promise for the treatment of pa-
tients with nonsurgically resectable primary and metastatic
liver metastatic disease
 23–26. It is known that hepatic tumors
receive 80–100% of blood supply from the hepatic ar-
tery 
27. Since liver tumors are fed mainly by arterial rather
than portal venous blood, a selective intraarterial radionu-
clide therapy (SIRT) via hepatic arterial administration of
Y-90 microspheres may deliver high radiation doses to tu-
mor tissue with minimal effect to the surrounding normal
liver parenchyma. In SIRT, Y-90 microspheres are used to
both embolize and irradiate tumors in the liver by deliver-
ing the microspheres through the hepatic artery 
26. In this
study, we presented our initial experience with early fol-
low-up results of SIRT with Y-90 microspheres for hepatic
neuroendocrine metastases.
Methods
We retrospectively evaluated the data from 10 patients
(male/female 5/5, mean ± SD age 48.7 ± 16.63 years; age
range 24–73 years) between April 2008 and August 2010,
who had SIRT with Y-90 microspheres (SIR-Spheres
® Sirtex
Medical, Lane Cove, Australia) for biopsy–proven progres-
sive unresectable hepatic NET metastases.
All patients were neither suitable nor responsive to
other local treatment options and showed inadequate re-
sponse to systemic chemotherapy. Prior to the treatment, all
patients were discussed in an interdisciplinary tumor board
composed of medical oncologist, interventional radiologist,
radiation oncologist, surgeon and an expert in nuclear medi-
cine. All patients had to give a formal written informed con-
sent after explanation of the whole treatment steps, alterna-
tive therapeutic options and possible complications.
The pretreatment evaluation included a medical history
compatible with time course of the disease, chemotherapy,
somatostatin analogues and/or interferon, laboratory tests
and comorbid disease. All patients had FDG-PET scan at
least 4 weeks prior to SIRT at least 4 weeks before to deter-
mine the extent of disease. Besides that, In-111 OctreoScan
whole body scan results were evaluated if available. Other
imaging studies, such as chest radiography, computed to-
mography (CT) scan of chest and abdomen, abdominal ultra-
sound and a bone scan are also done in determination of dis-
ease extent.
Adequate coagulation parameters and sufficient pulmo-
nary function to undergo arterial catheterization, and ade-
quate liver function [total biluribine (TB) level less than 2
mg/dL and alanine transaminase (ALT) or aspartate trans-
aminase (AST) levels less than five times of upper limit of
normal] were required in all patients. Patients who had pre-
vious external beam radiation therapy to the liver, ascites or
were in clinical liver failure, markedly abnormal synthetic
and excretory liver function tests (LFTs), complete portal
vein thrombosis, life threatening major extra hepatic metas-
tases, and those with expected survival < 3 months were not
considered for SIRT.
All patients with sufficient lab results had pretreatment
meticulous visceral angiography of the abdominal aorta, the
mesenteric artery and the celiac trunk including the common
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right and left hepatic artery was done to identify and occlude
non-target arteries with extrahepatic communication while
ruling out any high grade stenosis or occlusion which would
be contraindication for SIRT. Subsequently prophylactic
embolization of extrahepatic vessels such as the right gastric,
gastroduodenal or falciform artery was performed (Figure 1).
Noncorrectable flow to gastrointestinal tract was an exclu-
sionary criteria for SIRT. Technical details for performing
mesenteric angiography prior to SIRT have been described in
the literature 
28.
Fig. 1– Embolic coiling of the right gastric artery to
eliminate pathways for visceral shunting in a 44-year-old
male patient with hepatic metastatic medullary thyroid
cancer lesions
Following initial angiographic evaluation with/without
necessary prophylactic embolization of non-target extra he-
patic vessels, 150 MBq (4mCi) Technetium-99m Macro-
Aggregated Albumin (Tc-99m MAA) was injected via the
hepatic artery catheter or implanted port to assess the frac-
tion that passes through the liver to the lungs and the relative
distribution of MAA (and hence SIR-Spheres
®) between tu-
mor and normal liver. Anterior and posterior scintigraphic
images of the abdomen and thorax, and right lateral images
of the abdomen were obtained to rule out any unexpected
delivery of the activity (based on aberrant gastrointestinal
flow) and to estimate the percentage of injected activity
shunting from the liver into the lungs. Regions of interest are
drawn around the whole of lung fields and the whole of liver
field (Figure 2A). Additionally, a Single Photon Emission
Computed Tomography (SPECT) (64 projections, 360º, 25
seconds per projection) study was done (Millenium, GE) in 6
patients (Figure 2B). Lung shunt fraction (LSF) was deter-
mined using the following formula 
29: all embolization pro-
cedures were preferentially performed on the day of the
MAA scan before the administration of Y-90 radiomicro-
spheres.
A
Fig. 2 – Regions of interest were drawn around the whole of
lung fields and the whole of liver field on planar (A) Tc-99m
MAA perfusion scan; SPECT (B) images were also obtained
for simulation of Y-90 radiomicrospheres distribution before
SIRT (note the faint gastric and salivary uptake due to free
Tc-99m-pertechnetate)
Counts Lung (Anterior) × Counts Lung (Posterior)
LSF =
Counts Lung + Liver (Anterior) × Counts Lung + Liver (Posterior)
Since the particle size of the 99mTc-MAA is quite
comparable to that of the microspheres, the gamma scintig-
raphy provided valuable information concerning the pre-
dicted distribution of the therapeutic dose and allows the
quantification of hepato-pulmonary shunts
 23, 26. If the LSF is
between 10–15% and 15–20% then a SIR-Spheres
® dose re-
duction of 20% and 40% was done respectively. Although it
was not the case in our patients, LSF more than 20% would
be an absolute contraindication (with a dose to the lungs > 30
Gy) for SIRT. Additionally, there was no need for reduction
in shunting <10%.
Selective intraarterial radionuclide therapy procedure
was done in 2 to 3 weeks following the completion of the
above-mentioned procedures. Treatment of one side of the
liver was done for patients with disease limited to one lobe
on CT and/or FDG PET-CT scan. Treatment of both sides of
the liver was done by selective administration of Y-90 ra-
diomicrospheres into the right and left hepatic vascular bed
sequentially in the same session. A specially designed plexi-
glas delivery box provided by Sirtex Medical (Wilmington,
MA) was used for SIRT procedure (Figure 3). The body sur-
face area (BSA) method was used to calculate the prescribed
SIR-Spheres
® activity according to the following for-
mula 
26, 29:
e LiverVolum
e TumorVolum BSA
GBq Activity
+ −
=  ) 0.2 (
)  (
Immediate medication consisting of antiemetics and an-
algesics were prescribed for all patients. Additionally, lightStrana 344 VOJNOSANITETSKI PREGLED Volumen 68, Broj 4
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diet and sufficient hydration before and after SIRT were
maintained. The patients were discharged after one night
stay, and received a preventive gastric antisecretory treat-
ment (proton pump inhibitors) for 1 month and low dose
corticosteroids for one week to overcome flu-like reaction.
Since Y-90 is a pure beta emitter, Bremsstrahlung im-
aging is the only method for post treatment localization study
of radiomicrospheres. According to the patients’ clinical sta-
bility, post-therapeutic Bremsstrahlung imaging was per-
formed to confirm and document the distribution of SIR-
Spheres
® in all patients between 2 to 24 hours after SIRT
(Figure 4).
Fig. 4 – Bremsstrahlung imaging was performed to confirm
and document the distribution of SIR-Spheres
® after SIRT
All patients continued on low-dose steroids and pro-
ton-pump inhibitors for 1 week and 4 weeks after SIRT, re-
spectively. Complete blood count, liver function tests, and
routine biochemical tests were obtained at 24th hour after
SIRT, and then at every 4 weeks for the next 3 months.
Tumor response was assessed using RECIST criteria on
CT. Moreover, FDG PET scan was performed at 10 to 12
weeks after SIRT for the evaluation of metabolic response
and to differentiate viable components of the tumor from
necrotic tissue.
The quantitative data was analyzed using the Wilcoxon
Signed Ranks Test. Quantifiable data was given as mean ±
standard deviation (SD) (if no otherwise specified). A statis-
tically significant difference was considered when p values
<  0.05. All calculations were performed using SPSS for
Windows, Version 9.01.
Results
Sixteen SIRT procedures were carried out in 10 patients
with metastatic hepatic disease from NETs during a 24-
month period between April 2008 and May 2010. Out of the
10 patients, the primary NET site was the bronchus in 3 pa-
tients, the stomach in 1 patient, the medullary thyroid in 1
patient, the pancreas in 2 patients, the kolon/rectum in 2 pa-
tients and of unknown origin in 1 patient. The primary NETs
were classified as carcinoid in 8 patients, medullary thyroid
cancer in 1 patient and well differentiated unknown NET in
one patient (Table 1).
Nine out of 10 patients had multifocal metastases in both
lobes of the liver. Only one patient had multifocal disease in
the right lobe of the liver. Of the 10 patients, 6 patients had
whole liver treatments, and the other 4 patients had unilobar
treatments initially. While 6 out of the 10 patients had single
SIRT procedure, 2 patients had SIRT twice and 2 patients had
SIRT for three times (Table 1). Whole liver treatments were
administered either via common hepatic artery for bilobar dis-
ease or by the administration of 2 separate doses into the right
and left hepatic arteries (after adjusting the dose according to
the volume of the right and left hepatic lobes).
Because of the differences in the FDG avidity of NETs,
we used a combined approach for the calculation of tumor
volumes and normal livers. For the calculation of SIR-
Spheres
® activity to be administered, the total volume of the
all FDG avid hepatic metastases, and also normal liver vol-
umes were initially computed from the contoured and
thresholded region by counting the number of voxels in the
three-dimensional region and automatically multiplying by
the known volume of a voxel using MIM
® Software (MIM-
vista Corp., USA). Secondly, we reviewed the CT scans and
calculate the volumes of non FDG avid tumor sites with
positive radiologic findings for hepatic metastases using the
same software. Calculated mean ± SD liver involvement was
31.1 ± 10.43% (range 10–45%).
None of the patients showed marked pulmonary activity
on Tc-99m MAA scan. The mean ± SD pulmonary shunt
was 6.04 ± 2.47% (range 3.4–10.03%). There was no scin-
tigraphically detectable extrahepatic uptake on planar Tc-
99m MAA scan. Furthermore, we did not observe any addi-
tional extrahepatic uptake on SPECT in the patients (4/10)
where available.
Fig. 3 – A specially designed plexiglas delivery box provided
by Sirtex Medical (Lane Cove, Australia) which is used for
injecting Y-90 radiomicrospheresVolumen 68, Broj 4 VOJNOSANITETSKI PREGLED Strana 345
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The mean ± SD administered SIR-Spheres
® activity
was 1.49  ±  0.42 GBq (range 0.72–2.21 GBq) in all pa-
tients. The 4 patients with bilobar disease were treated with
whole liver administration of SIR-Spheres
® with the activity
of 1.62 ± 0.26 GBq (range 1.40–2.20 GBq) at a single ses-
sion. The other 6 patients had unilobar treatment initially
with the activity of 1.40 ± 0.52 GBq (range 0.7–2.02 GBq)
initially. Three out of these 6 patients with unilobar injection
had opposite lobe treatment in the follow-up. These treat-
ments delivered a dose of 99.73 ± 66.36 Gy (range 49–420.8
Gy) to the target tumors. The estimated dose to the lungs and
normal liver 4.45 ± 1.95 Gy (2.4–8.5 Gy) and 26.73 ± 14.19
Gy (range 5–58.9 Gy) respectively (Table 1)
 29.
We experienced difficulty in the administration of SIR-
Spheres
® in 2 patients because of vessel spasm during the
procedure. Both of the 2 patients were planned to have
whole liver treatment (Cases 8 and 10). But both of them had
left hepatic vessel spasm, shifting to treatment procedure
from whole liver to only right lobe therapy. They had similar
celiac axis with no definitive anatomic variation. The first
patient had retreatment to the opposite lobe 4 weeks later.
The second one is still on follow-up and scheduled for the
left lobe treatment.
In our study group, there was no patient with portal
vein thrombosis. The mean ± SD follow-up time for SIR-
Spheres
® therapy was 6  ±  2.8 months (range 3–28
months). Although, almost all patients reported some de-
gree of mild-to-moderate abdominal pain, nausea, leth-
argy, anorexia, and fever from 1 week to 1 month after the
treatment, no one needed intravenous narcotics and anti-
emetics. Liver function tests during the follow-up period
were stable in all patients. However, we experienced mild
to moderate increase in TB, ALT or AST, gamma glu-
tamyl transferase (GGT) and serum alkaline phosphates
(ALP) levels in 70% of all patients. Among these parame-
ters, post treatment AST, GGT and ALP levels [39 (27.7–
55.2)% and 69 (55.5–141.7)%; 137.5 (116.5–238.7)% re-
spectively] were significantly higher than baseline values
[26 (21–33)%, 36 (27.7–120.7)% and 116 (102.5–219.2)%
respectively] (p ≤ 0.05). On the other hand, the increase in
ALT (p = 0.080)  and  TB  levels  (p = 0.104)  after  SIRT
compared to baseline levels were not statistically signifi-
cant. The patient with medullary thyroid cancer developed
transient elevation of serum amylase which resolved in 48
hours without any medication. There was no case with ra-
diation pneumonitis or radiation induced liver disease
(RILD).
Of the 10 patients, 3 showed complete response (CR), 5
showed partial response (PR) and one showed stable disease
(SD) of the target lesions according to RECIST criteria (Fig-
ures 5a and 5b). One patient showed progressive disease
(PD) on follow-up. One of the patients with PR for hepatic
tumors died of extensive bone, soft tissue and solid organ
metastases 18 month after SIRT (Table 1). The data repre-
senting the extent of hepatic involvement, administered ac-
tivities, estimated tumor doses with tumor responses are pre-
sented in Table 1.Strana 346 VOJNOSANITETSKI PREGLED Volumen 68, Broj 4
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Discussion
Neuroendocrine tumors are heterogeneous group of
neoplasms with endocrine metabolism and special histologi-
cal structure. Despite the lack of private residential areas,
90% of NETs is derived from the gastroenteropancreatic
system. They are generally low grade malignancies and tend
to grow slowly. Although metastases from NETs are rare in
tumors less than 2 cm, presence of liver metastases is one of
the worst prognostic factors. Resection and successful local
treatments can be related with long term survival 
30, but the
treatments are seldom curative, and the 5-year survival rate
for patients who have unresected liver metastasis is between
25% and 50% 
31. Therefore, if metastases are limited to the
liver and the surgical resection is not possible, other local
interventional treatment options should be considered, even
in the presence of extrahepatic metastases. Although, TAE,
TACE or RFA may be one of the local treatment options,
each of them has its own restrictions in the appropriate pa-
tient selection 
32, and also in application which limits their
effectiveness as a single therapy 
3.
SIRT, a form of intraarterial brachytherapy, is a tech-
nique in which glass (TheraSphere
®) or resin (SIR-Spheres
®)
particles are labeled with Y-90. The radioisotope Y-90 is a
pure  β emitter with no primary gamma radiation. SIR-
Sphere, a permanent implant, is not metabolized or excreted
and it stays permanently in the liver in the form of biocom-
patible particles, measuring approximately 20 to 60 microns.
The mean energy of the particles is 0.9367 MeV, has a mean
tissue penetration of 2.5 mm, and has a maximum penetra-
tion of 10 mm. In therapeutic use, requiring the isotope to
decay to infinity, 94% of the radiation is delivered in 11
days 
33. Administration of radiomicrospheres is performed
via a catheter placed in the hepatic artery delivering the
spheres to the capillary bed where they are fixed and decay
with the physical half-life of Y-90 (64 h). Malignant liver
tumors are fed mainly by hepatic arterial system rather than
portal venous blood. Therefore, the dominant arterial flow of
Fig. 5a – Abdominal CT scan before (top raw) and 3 months (bottom raw) after SIRT, showed partial response in a 21-year-
old male patient with multiple metastatic liver lesions from carcinoid tumor (case N
o 3)
Fig. 5b – Corresponding transaxial (1st column), sagittal (2nd column) and coronal (3rd column) slices of the pretreatment
(top raw) and posttreatment (bottom raw) FDG PET studies showed noticeable metabolic response in metastatic sites in the
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malignant tissue allows the delivery of high doses of radia-
tion to tumors while keeping the exposure of the healthy
liver at minimum with selective microsphere distribution.
At our institution, 48 SIRT procedures were carried out
in 38 patients during a 28-month period between April 2008
and August 2010. Of the 38 patients, 10 patients suffering
from extensive hepatic metastatic disease from NET were in-
cluded in this study. Although, there are some physical dif-
ferences in quality, size and particle number, Tc-99m MAA
is the current standard for the evaluation of hepatic arterial
flow. Since all aberrant and non-target vessels were coiled
prior to Y-90 therapy in all patients, we did not observe any
extra hepatic activity on Tc-99m MAA scan. Moreover, we
observed great concordance with pre-SIRT Tc-99m MAA
scan and post-therapeutic Bremsstrahlung imaging. We per-
formed Bremsstrahlung imaging as soon as possible, but no
later than 24 hours after the radioembolization as recom-
mended in the literature 
29. Although we did not observe any
hormonal crisis, we experienced vasospasm during Y-90 ra-
diomicrosphere injection in 2 patients. As reported before,
vessel spasm is not unusual during the Y-90 infusion. There-
fore, it may be crucial to use microcatheter injections as rec-
ommended, particularly if the vessels are small in caliber or
demonstrate significant tortuosity 
34. Moreover, it may be
helpful to use short acting somatostatin analogs for sympto-
matic patients presenting with carcinoid related symptoms
before local treatment procedures. Most of our patients, ex-
cept cases N
o 1 and 10, were on sandostatin treatment during
the SIRT procedure.
As RECIST are commonly used to evaluate the success
of a treatment, we used CT scan data to document therapy
response 
29. Of the 10 patients, 5 had both hepatic and extra-
hepatic metastases on pre-SIRT FDG PET scan (Table 1).
One out of 10 patients showed PD for hepatic metastases de-
spite SIRT. Of the 10 patients, 5 showed PR after SIRT. One
patient with PR for hepatic metastases showed new bone and
soft tissue metastatic sites on follow-up (case N
o 3) and died
of systemic spread of metastatic disease 18 months after
SIRT while on streptozotocin and sandostatin treatment. The
other 3 patients showed CR for hepatic metastases. The pa-
tient with medullary thyroid cancer (case N
o 1) had bilateral
cervical lymph node metastases, and had lymph node dissec-
tion after SIRT. The patient with bronchial carcinoid tumor
(case N
o 2) had external radiotherapy for bone metastases
concomitantly with SIRT. Fortunately, the bone and hepatic
metastases completely resolved on follow-up in this patient.
The other patient with bronchial carcinoid tumor (case N
o
10) showed CR to SIRT at the beginning. However, we ob-
served new mediastinal lymph nodes and solitary lung nod-
ule, showing markedly increased FDG uptake, very suspi-
cious for recurrence on the recent FDG PET-CT in the same
patient 4 months after completing the therapy.
The tolerability of SIRT for all patients was very good.
We observed minor side effects (fatigue, nausea, transient
elevation in serum liver enzymes and abdominal pain) which
resolved in 1 week. No severe side effect, treatment related
mortality, radiation hepatitis or veno-occlusive liver failure
was seen in our patient population. The common side effect
was a slight increase in serum ALP and GGT levels. These
results are concordant with the procedure guidelines and pre-
viously published reports 
26.
The response rates in this preliminary study are consis-
tent with previously published data on large series of patients
35, 36. According to the CT data, we observed 90% response
rate (CR – 30%; SD – 10%; PR – 50%). PD was observed in
10% (1/10) of all patients on CT scan. However, patients
with PD or SD on CT, have either stable or decreased FDG
uptake values on FDG PET study. Therefore, from our lim-
ited experience we may conclude that FDG-PET-CT and
quantitative FDG data such as SUVmax, SUV mean, and
Tissue Lesion Glycolysis (TLG) may have a crucial role in
the evaluation of response to SIRT in future.
The results of this study should be considered prelimi-
nary and exploratory by nature in this study involving a lim-
ited number of patients. Moreover, not having serum tumor
markers such as Chromogranine A, Neurokinin-A or HIAA,
and In-111 OctreoScan in all patients, are the main draw-
backs of this study. We still need to improve our practice and
knowledge regarding radiation dosimetry and fractionation,
including more than one application of microspheres, imag-
ing and follow-up guidelines and long-term results.
Conclusion
From our limited experience, SIRT with Y-90 radiomi-
crospheres for liver metastases from NETs seems to be safe
and efficacious with limited toxicity. However, there is a
need to combine Y-90 radiomicrospheres treatment with
systemic therapeutics for the patients with extra hepatic me-
tastases to control the disease.
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